HOME >> MEDICINE >> NEWS
Biomolecule studied for medical uses

DURHAM, N.C. -- Duke University Chemistry Department researchers are creating unique polymers out of naturally occurring building blocks that don't provoke immune reactions and in some cases also biodegrade in the body. The tree-like, globular-shaped substances are being evaluated for a variety of medical uses.

Called biodendrimers, these structures are prepared by systematically reacting acids with alcohols to form what chemists call "esters." The results are branching molecular chains with finger-like ends that can form sticky and tenacious links with other substances.

These characteristics make them "ideal candidates for medical and tissue engineering applications," said Mark Grinstaff, the assistant chemistry professor who heads the Duke team. One potential application, which Duke Medical Center eye researchers are beginning to test, is a glue that could "close a wound and then be dissolved as new tissue grows in to repair the wound site," he added in an interview.

"It could really potentially change the way we do corneal surgery," added Dr. Terry Kim, associate director of the Corneal and Refractive Surgery Service at the Duke Eye Center and a medical center assistant professor of ophthalmology.

Another possibility, which biomedical researchers at Duke's Pratt School of Engineering have also started investigating, would be using such biodendrimers as scaffolding to help induce cells to repair damaged human joints.

"Biodendrimers appear to interact with cells in completely novel manners," said Lori Setton, assistant professor and Harold L. Yoh Faculty Scholar in the Pratt School's Department of Biomedical Engineering. Because of its promise, Grinstaff's research just received $250,000 in funding from the Johnson & Johnson Focused Giving program, established to stimulate exploration in medical science. Other funding sources include the Pew, Sloan and Dreyfus foundations.

In a spring 2001 issue of the Journal of the Americ
'"/>

Contact: Monte Basgall
monte.basgall@duke.edu
919-681-8057
Duke University
30-Aug-2001


Page: 1 2 3 4

Related medicine news :

1. Technology that could double the effectiveness of cancer drugs studied at Yale
2. New global trials help to make FOSRENOL(R) the most extensively studied modern phosphate binder
3. Mind-body connection in placebo surgery trial studied by University of Denver researcher
4. Possible brain cancer-air pollution link to be studied
5. Investigational mesh jackets studied as an experimental therapy for heart failure
6. Venlafaxine XR, first SNRI studied for social anxiety disorder
7. New pathway for treating hypertension-related kidney failure studied
8. Intensification therapy studied in head and neck cancer
9. Chronic disease: the overlooked & understudied epidemic
10. Advertising by academic medical centers may risk eroding public trust, says study
11. NIH state-of-the-science panel calls for demedicalization of menopause

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Biomolecule studied for medical uses

(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ... directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... breached its fiduciary duties to shareholders. On ... investing website reporting that Advaxis had misrepresented the clinical ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Cached News: